FDA declines Galderma’s Botox rival application after manufacturing-site inspection

The Swiss skincare company said it is taking corrective and preventive actions after the U.S. regulator issued a complete response letter on RelabotulinumtoxinA, three years after an earlier submission was also rejected.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.